Precision BioSciences Inc DTIL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
-
Precision BioSciences Announces Inclusion in the Russell 2000® Index Expanding Market Visibility with Institutional Investors
-
Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026
-
Precision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Presented at European Association for the Study of the Liver Congress 2026
-
Precision BioSciences Presents New Preclinical Data Supporting the Advancement of PBGENE-DMD into Clinic at the American Society of Gene & Cell Therapy 2026 Annual Meeting
-
Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update
-
Precision BioSciences to Report First Quarter 2026 Financial Results on May 5, 2026
-
Precision BioSciences Activates First Clinical Trial Site and Begins Patient Enrollment in Phase 1/2 FUNCTION-DMD Study
Trading Information
- Previous Close Price
- $9.16
- Day Range
- $8.55–9.17
- 52-Week Range
- $3.53–9.62
- Bid/Ask
- $8.37 / $10.05
- Shares Outstanding
- 25.80M
- Market Cap
- $226.03M
- Volume/Avg
- 579,602 / 394,856
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3.42
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 66
Valuation
|
Metric
|
DTIL
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.14 |
Price/Sales | 3.42 |
Price/Cash Flow | — |
Price/Earnings
DTIL
Financial Strength
|
Metric
|
DTIL
|
|---|---|
Quick Ratio | 0.00 |
Current Ratio | 14.02 |
Interest Coverage | −34.10 |
Quick Ratio
DTIL
Profitability
|
Metric
|
DTIL
|
|---|---|
Return on Assets (Normalized) | −31.96% |
Return on Equity (Normalized) | −74.44% |
Return on Invested Capital (Normalized) | −55.11% |
Return on Assets
DTIL
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|p#&qqqC | LOCK|#k%pM | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|Y^f@$Z | LOCK|%hwL | $70B | |||
| argenx SE ADR
ARGX
| LOCK|S#?qN?? | LOCK|xk | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|Xfj<%# | LOCK|$pMwm | $40B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|SP#&wB | LOCK|<# | $36B | |||
| Moderna Inc
MRNA
| LOCK|@l^>Zz> | LOCK|P# | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|&C^S>Y$V | LOCK|J>zN | $25B | |||
| Incyte Corp
INCY
| LOCK|<BX&q< | LOCK|<Z! | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|gjLmNf | LOCK|<CS | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|!Dl>JwD | LOCK|%@? | $17B |
United States